Core Insights - Astrana Health reported a remarkable year-on-year revenue growth of 99.7%, reaching $956 million, which exceeded Wall Street's estimates by 0.6% [1][5] - The company has shown strong annualized revenue growth of 47.7% over the last two years, indicating a recent acceleration in demand [1] - Astrana Health's sales have grown at a compounded annual growth rate of 33.3% over the last five years, outperforming the average healthcare company [2] Financial Performance - The company's free cash flow margin decreased to 0.8% from 6.6% in the same quarter last year, and the operating margin fell to 2% from 5.9% [4] - Astrana Health's full-year revenue guidance was lowered to $3.14 billion, which is 1.9% below previous estimates [4] - The GAAP profit for the company was reported at $0.01 per share, significantly below analysts' consensus estimates by 97.6% [5] Profitability Trends - Astrana Health's operating margin has decreased by 14 percentage points over the last five years, indicating rising expenses that could not be passed onto customers [8] - The operating margin for Q3 was 2%, down 3.9 percentage points year on year, reflecting less efficiency due to faster-growing expenses compared to revenue [9] - Earnings per share (EPS) declined by 27.1% annually over the last five years, despite revenue growth, suggesting reduced profitability on a per-share basis [10] Market Expectations - Analysts project a revenue growth of 37.2% over the next 12 months, indicating a slowdown compared to the previous two years but still reflecting confidence in the company's products and services [6] - Wall Street expects Astrana Health's full-year EPS to grow 877% over the next 12 months, despite the current low EPS of $0.01 [12]